Three groups, comprising normal subjects (n = 10), aspirin-sensitive asthmatics (ASA+; n = 10) and aspirin-insensitive asthmatics (ASA––; n = 10) were entered into a blinded, parallel group study to assess the modulating effect of aspirin (ASA; 0.0275, 0.275, 1.385, 2.75, 6.9, 13.8 and 27.5 μM) on lymphocyte proliferation in vitro, either alone or in combination with the mitogen, phyto-hemagglutinin (PHA; 10, 25, 50,100, 200 and 500 μg/ml). The percentage and absolute numbers of CD4-positive T cells (normals: 51.3%; ASA+: 51.1%; ASA-: 46.1%; p = 0.4038) and CD8-positive T cells (normal: 27.5%; ASA+: 26.4%; ASA––: 28.4%; p = 0.8408) did not differ significantly between the groups. Significant differences in mean PHA responses between ASA+, ASA–– and normal subjects were observed when peripheral blood lymphocytes (PBL) were exposed to PHA concentrations over the range 10–50 μg/ml; PHA 10 μg/ml (p < 0.005), PHA 25 μg/ml (p < 0.005) and PHA 50 μg/ml (p < 0.01), the lowest and highest proliferative responses being obtained with PBL from ASA+ and ASA––, respectively. However, at higher PHA concentrations (100–500 μg/ml), differences between the three groups were not observed. When ASA was added in combination with PHA, augmentation of the PHA response was observed with cells from all three groups but was most marked in the ASA+ group, especially at lower PHA concentrations (10-50 μg/ml) in combination with 0.275–13.8 μM ASA. When ASA was added alone, significant proliferation was obtained with cells from normal subjects at a concentration of 6.9 μM, while 13.8 and 27.5 μM were required to produce proliferation in ASA+ and ASA––. When these data were analysed further, a subset (n = 9) of ASA responders was identified of whom the majority (n = 5) were ASA+ (p < 0.05). This study suggests that ASA not only enhances lymphocyte proliferation in response to PHA but also induces proliferation per se. Although the mechanisms involved are unclear, the data indicate that further study of lymphocytes from both ASA+ and ASA–– may be warranted.

Keywords:
Asthma, Lymphocytes, Aspirin
This content is only available via PDF.
© 1993 S. Karger AG, Basel
1993
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.